Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020.

Adalberta Lima Martins, Rodrigo Galhardi Gasparini, Ligia Yukie Sassaki, Rogerio Saad-Hossne, Alessandra Mileni Versut Ritter, Tania Biatti Barreto, Taciana Marcolino, Claudia Yang Santos
Author Information
  1. Adalberta Lima Martins: Espirito Santo Health Office, State Office for Pharmaceutical Assistance, Espirito Santos 29056-030, Brazil.
  2. Rodrigo Galhardi Gasparini: Department of Gastroenterology, Specialized Medical Center, Marília 17502-020, Brazil.
  3. Ligia Yukie Sassaki: Department of Gastroenterology, Sao Paulo State University, Medical School, Botucatu 18618-687, Brazil.
  4. Rogerio Saad-Hossne: Department of Gastroenterology, Sao Paulo State University, Medical School, Botucatu 18618-687, Brazil.
  5. Alessandra Mileni Versut Ritter: Real World Evidence, IQVIA Brazil, Sao Paulo 04719-002, Brazil.
  6. Tania Biatti Barreto: Department of Gastroenterology, Takeda Pharmaceuticals Brazil, Sao Paulo 04794-000, Brazil.
  7. Taciana Marcolino: Department of Gastroenterology, Takeda Pharmaceuticals Brazil, Sao Paulo 04794-000, Brazil.
  8. Claudia Yang Santos: Department of Gastroenterology, Takeda Pharmaceuticals Brazil, Sao Paulo 04794-000, Brazil. clausantos2910@gmail.com.

Abstract

BACKGROUND: This was an observational, descriptive, and retrospective study from 2011 to 2020 from the Department of Informatics of the Brazilian Healthcare System database.
AIM: To describe the intestinal complications (IC) of patients with ulcerative colitis (UC) who started conventional therapies in Brazil´s public Healthcare system.
METHODS: Patients ≥ 18 years of age who had at least one claim related to UC 10 revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) code and at least 2 claims for conventional therapies were included. IC was defined as at least one claim of: UC-related hospitalization, procedures code for rectum or intestinal surgeries, and/or associated disease defined by ICD-10 codes (malignant neoplasia of colon, stenosis, hemorrhage, ulcer and other rectum or anus disease, megacolon, functional diarrhea volvulus, intussusception and erythema nodosum). Descriptive statistics, annual incidence, and incidence rate (IR) [per 100 patient-years (PY)] over the available follow-up period were cal-culated.
RESULTS: In total, 41229 UC patients were included (median age, 48 years; 65% women) and the median (interquartile range) follow-up period was 3.3 (1.8-5.3) years. Conventional therapy used during follow-up period included: mesalazine (87%), sulfasalazine (15%), azathioprine (16%) or methotrexate (1%) with a median duration of 1.9 (0.8-4.0) years. Overall IR of IC was 3.2 cases per 100 PY. Among the IC claims, 54% were related to associated diseases, 20% to procedures and 26% to hospitalizations. The overall annual incidence of IC was 2.9%, 2.6% and 2.5% in the first, second and third year after the first claim for therapy (index date), respectively. Over the first 3 years, the annual IR of UC-related hospitalizations ranged from 0.8% to 1.1%; associated diseases from 0.9% to 1.2% - in which anus or rectum disease, and malignant neoplasia of colon were the most frequently reported; and procedure events from 0.6% to 0.7%, being intestinal resection and polyp removal the most frequent ones.
CONCLUSION: Study shows that UC patients under conventional therapy seem to present progression of disease developing some IC, which may have a negative impact on patients and the burden on the health system.

Keywords

References

  1. Drugs Context. 2019 Apr 29;8:212572 [PMID: 31065290]
  2. Aliment Pharmacol Ther. 2017 Jun;45(12):1481-1492 [PMID: 28449361]
  3. Cien Saude Colet. 2017 Apr;22(4):1055-1064 [PMID: 28444033]
  4. Naika. 1968 Oct;22(4):961-8 [PMID: 5707883]
  5. Cad Saude Publica. 2006 Jan;22(1):19-30 [PMID: 16470279]
  6. J Gastrointest Surg. 2017 Jul;21(7):1159-1165 [PMID: 28484890]
  7. Aliment Pharmacol Ther. 2015 Jun;41(11):1066-78 [PMID: 25855078]
  8. Therap Adv Gastroenterol. 2009 Mar;2(2):99-108 [PMID: 21180538]
  9. Gut. 1985 Feb;26(2):158-63 [PMID: 3967834]
  10. Gastroenterology. 2021 Apr;160(5):1570-1583 [PMID: 33359090]
  11. Therap Adv Gastroenterol. 2020 Jul 9;13:1756284820931739 [PMID: 32695230]
  12. Clin Gastroenterol Hepatol. 2017 Jun;15(6):857-863 [PMID: 27856364]
  13. Curr Drug Targets. 2011 Sep;12(10):1440-7 [PMID: 21466486]
  14. Gut Liver. 2015 Jan;9(1):18-27 [PMID: 25547087]
  15. Updates Surg. 2022 Apr;74(2):637-647 [PMID: 35217982]
  16. United European Gastroenterol J. 2018 Mar;6(2):322-330 [PMID: 29511562]
  17. World J Gastroenterol. 2015 Jan 28;21(4):1197-206 [PMID: 25632193]
  18. Aliment Pharmacol Ther. 2014 Apr;39(7):660-71 [PMID: 24506179]
  19. Gastroenterology. 2007 Oct;133(4):1099-105; quiz 1340-1 [PMID: 17919486]
  20. Am J Gastroenterol. 2015 Sep;110(9):1324-38 [PMID: 26303131]
  21. N Engl J Med. 2013 Aug 22;369(8):699-710 [PMID: 23964932]
  22. World J Gastroenterol. 2011 Jul 21;17(27):3204-12 [PMID: 21912469]
  23. J Gastroenterol Hepatol. 2007 Sep;22(9):1450-5 [PMID: 17716349]
  24. PLoS One. 2018 Jun 21;13(6):e0199446 [PMID: 29928006]
  25. Clin Gastroenterol Hepatol. 2018 Mar;16(3):343-356.e3 [PMID: 28625817]
  26. BMJ. 2000 Apr 22;320(7242):1119-23 [PMID: 10775225]
  27. Vojnosanit Pregl. 1974 Nov-Dec;31(6):420 [PMID: 4614568]
  28. Aliment Pharmacol Ther. 2020 May;51(9):852-860 [PMID: 32201971]
  29. Am J Gastroenterol. 2019 Jun;114(6):874-883 [PMID: 30908297]
  30. Neurogastroenterol Motil. 2015 Jul;27(7):1032-7 [PMID: 25940976]
  31. BMC Gastroenterol. 2018 Jun 18;18(1):87 [PMID: 29914399]
  32. Clin Exp Gastroenterol. 2018 Oct 30;11:423-429 [PMID: 30464570]
  33. Inflamm Bowel Dis. 2012 Jul;18(7):1356-63 [PMID: 22162423]
  34. GE Port J Gastroenterol. 2018 Mar;25(2):74-79 [PMID: 29662931]
  35. Int J Colorectal Dis. 2019 Apr;34(4):699-710 [PMID: 30685791]
  36. J Clin Med. 2020 Aug 14;9(8): [PMID: 32823997]

MeSH Term

Humans
Female
Middle Aged
Male
Colitis, Ulcerative
Brazil
Retrospective Studies
Azathioprine
Neoplasms

Chemicals

Azathioprine

Word Cloud

Created with Highcharts 10.0.0IC0patientsyears23therapyUCconventionaldisease1intestinalcomplicationscolitisleastclaimrectumassociatedannualincidenceIRfollow-upperiodmedianfirst20112020BrazilianHealthcareulcerativetherapiessystemageonerelatedICD-10codeclaimsincludeddefinedUC-relatedproceduresmalignantneoplasiacolonanus100PYConventional1%diseaseshospitalizations9%6%IntestinalBACKGROUND:observationaldescriptiveretrospectivestudyDepartmentInformaticsSystemdatabaseAIM:describestartedBrazil´spublicMETHODS:Patients1810revisionInternationalStatisticalClassificationDiseasesRelatedHealthProblemsof:hospitalizationsurgeriesand/orcodesstenosishemorrhageulcermegacolonfunctionaldiarrheavolvulusintussusceptionerythemanodosumDescriptivestatisticsrate[perpatient-years]availablecal-culatedRESULTS:total412294865%womeninterquartilerange8-5usedincluded:mesalazine87%sulfasalazine15%azathioprine16%methotrexateduration98-4OverallcasesperAmong54%20%26%overall5%secondthirdyearindexdaterespectivelyranged8%2%-frequentlyreportedprocedureevents7%resectionpolypremovalfrequentonesCONCLUSION:StudyshowsseempresentprogressiondevelopingmaynegativeimpactburdenhealthtreatedBrazilPublichealthcareRealworldUlcerative

Similar Articles

Cited By (2)